They have previously indicated a reduction in R&D costs. Whether or not that will be enough to offset the increased operating costs, we'll have to wait and see.
If not this quarter, then we should definitely hit it the following.
- Forums
- ASX - By Stock
- NET
- Ann: Record Customer Receipts of $5.8m in September Quarter
NET
netlinkz limited
Add to My Watchlist
0.00%
!
0.3¢

Ann: Record Customer Receipts of $5.8m in September Quarter, page-16
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.63M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NET (ASX) Chart |
Day chart unavailable
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online